您的位置: 专家智库 > >

国家自然科学基金(81270636)

作品数:9 被引量:10H指数:2
相关作者:王季石吴莉赵鹏李梦醒张燕更多>>
相关机构:贵州省人民医院贵州医科大学贵阳医学院附属医院更多>>
发文基金:国家自然科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 9篇中文期刊文章

领域

  • 9篇医药卫生

主题

  • 5篇细胞
  • 4篇白血
  • 3篇造血
  • 3篇造血干
  • 3篇造血干细胞
  • 3篇造血干细胞移...
  • 3篇干细胞
  • 3篇干细胞移植
  • 3篇白血病
  • 2篇阳性
  • 2篇伊马替尼
  • 2篇伊马替尼治疗
  • 2篇增多症
  • 2篇组织细胞
  • 2篇组织细胞增多
  • 2篇组织细胞增多...
  • 2篇文献复习
  • 2篇细胞增多
  • 2篇淋巴
  • 2篇甲磺酸

机构

  • 5篇贵州省人民医...
  • 5篇贵州医科大学
  • 2篇贵阳医学院附...

作者

  • 6篇王季石
  • 5篇吴莉
  • 2篇张燕
  • 2篇李梦醒
  • 2篇赵鹏
  • 1篇卢英豪
  • 1篇李艳菊
  • 1篇孙志强
  • 1篇杨洁

传媒

  • 4篇现代医药卫生
  • 2篇Chines...
  • 1篇实用医学杂志
  • 1篇医学研究杂志
  • 1篇中国组织工程...

年份

  • 1篇2020
  • 1篇2019
  • 2篇2018
  • 1篇2017
  • 3篇2014
  • 1篇2013
9 条 记 录,以下是 1-9
排序方式:
亲缘异基因造血干细胞移植联合甲磺酸伊马替尼治疗Ph阳性白血病被引量:1
2014年
背景:造血干细胞移植是可以治愈Ph+白血病有效方法,甲磺酸伊马替尼是一种高度特异的酪氨酸激酶抑制剂,能抑制BCR/ABL酪氨酸激酶活性,在Ph+白血病中的应用越来越多。目的:探讨甲磺酸伊马替尼联合亲缘异基因造血干细胞移植治疗Ph+白血病的临床疗效。方法:回顾性分析2011年1月至2012年10月采用亲缘异基因造血干细胞移植联合甲磺酸伊马替尼治疗12例Ph+白血病的疗效并文献复习。结果与结论:12例患者移植后均获得造血重建,移植后中性粒细胞和血小板植活的中位时间分别为15 d和18 d;发生Ⅱ度急性移植物抗宿主病7例,Ⅲ度急性移植物抗宿主病1例,局限型慢性移植物抗宿主病7例,广泛型慢性移植物抗宿主病3例;无白血病存活率为67%,移植相关死亡率为25%。行HLA匹配亲缘造血干细胞移植者的总体存活率为75.0%。平均无病生存8.5个月(7-17个月),BCR/ABL转阴时间2-5个月。亲缘异基因造血干细胞移植前、后联合甲磺酸伊马替尼治疗Ph+白血病,具有降低移植前白血病细胞负荷,抑制残留白血病细胞增殖,促进供者完全嵌合状态的转变,是一种安全有效的治疗方法。
李梦醒王季石张燕孙志强赵鹏卢英豪
关键词:白血病甲磺酸伊马替尼
Upregulated heme oxygenase-1 expression of mouse mesenchymal stem cells resists to chemotherapy-induced bone marrow suppression
2014年
Background Bone marrow hematopoietic function suppression is one of the most common side effects of chemotherapy.After chemotherapy,the bone marrow structure gets destroyed and the cells died,which might cause the hematopoietic function suppression.Heme oxygenase-1 (HO-1) is a key enzyme of antioxidative metabolism that associates with cell proliferation and resistance to apoptosis.The aim of this study was to restore or resist the bone marrow from the damage of chemotherapy by the HO-1 expression of mouse mesenchymal stem cells (mMSCs) homing to the mice which had the chemotherapy-induced bone marrow suppression.Methods One hundred and sixty female Balb/c mice (6-8-weeks old) were randomly divided into four groups.Each group was performed in 40 mice.The control group was intraperitoneally injected for 5 days and tail intravenously injected on the 6th day with normal saline.The chemotherapy-induced bone marrow suppression was established by intraperitoneally injecting cyclophosphamide (CTX) into the mice which performed as the chemotherapy group.The mMSCs were tail intravenously injected into 40 chemotherapically damaged mice which served as the mMSCs group.The difference between the HO-1 group and the mMSCs group was the injected cells.The HO-1 group was tail intravenously injected into the mMSCs that highly expressed HO-1 which was stimulated by hemin.The expression of HO-1 was analyzed by Western blotting and RT-PCR.Cell proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.Histopathologic examinations were performed 1 week after injection.Results Compared with the control group,the expression levels of HO-1 mRNA and protein were significantly higher in the HO-1 group (all P <0.05),even obviously than the mMSCs group.CTX treatment induced apoptosis and inhibited proliferation.After injected,the white blood cell (WBC),red blood cell (RBC) and platelet (PLT) declined fast and down to the bottom at the 7th day.The bone marrow
Chen ShuyaWang JishiFang QinGao RuiShi QianyingZhang HuiZhao Jiangyuan
异基因造血干细胞移植前后联合伊马替尼治疗Ph染色体阳性的白血病被引量:1
2013年
目的:观察异基因造血干细胞移植前后联合伊马替尼治疗Ph+白血病的临床疗效。方法:回顾性分析2011年1月至2013年2月采用亲缘异基因造血干细胞移植联合甲磺酸伊马替尼治疗的Ph染色体阳性白血病15例的临床资料,并随访生存期。结果:15例患者移植后均获得造血重建,患者输注单个核细胞的中位数为4.32×10^8/kg。输注CD34+细胞中位数为3.15×10^6/kg。发生Ⅱ度急性移植物抗宿主病(aGVHD)9例.Ⅲ度aGVHD1例,局限型慢性移植物抗宿主病(cGVHD)10例,广泛型cGVHD3例;无白血病存活率为73-3%。行HLA匹配亲缘HSCT者的总体存活率为80%。结论:亲缘异基因造血干细胞造移植前、后联合伊马替尼治疗Ph(+)白血病,具有降低移植前白血病细胞负荷,抑制残留白血病细胞增殖,促进供者完全嵌合状态的转变,是一种安全有效的治疗方法。
李梦醒王季石张燕赵鹏李艳菊
关键词:造血干细胞移植甲磺酸伊马替尼
朗格汉斯细胞组织细胞增生症1例报道并文献复习被引量:3
2017年
朗格汉斯细胞组织细胞增生症(Langerhans cell histiocytosis,LCH)是单核-吞噬系统细胞单克隆增生导致器官功能障碍为特征的肿瘤,界于良恶性肿瘤之间,国际组织细胞协会将其归类于组织细胞/网状细胞增殖性疾病。其临床罕见、发病较隐匿、
张奉齐王季石吴莉
关键词:组织细胞增多症免疫组织化学病例报告
Over-expression of heme oxygenase-1 in peripheral blood predicts the progression and relapse risk of chronic myeloid leukemia
2014年
Background There are limited eligible clinical markers at present to monitor the progress of chronic myeloid leukemia (CML).Heme oxygenase-1 (HO-1),as one of the most important oxidation-regulating enzymes in vivo,suggests the onset and progression of cancer when highly expressed.Furthermore,HO-1 level is related with the occurrence and development of hematological diseases.But the relationship between HO-1 expression and progression/relapse of CML has seldom been studied hitherto.This study aimed to investigate the relationship between them to find out a new molecular marker for prediction.Methods A total of 60 peripheral blood and bone marrow (BM) samples from 25 CML patients in different phases were collected respectively to detect the expressions of HO-1 and bcr/abl using real-time PCR.Routine blood test was performed to detect the changes of leukocyte and platelet counts.The proportion of primitive cells in BM was detected by flow cytometry.The relationship between high HO-1 expression and CML progression and relapse was explored by the analysis of variance by Wilcoxon test and linear regression analysis.The diagnostic accuracy and cutoff values were determined by receiver operating characteristic curve.Results Relative expression of HO-1 mRNA in CML patients peripheral blood was significantly higher than that of donors (P 〈0.0001),which were 0.57±3.78 and (1.417±1.125)×10-6,respectively.HO-1 expression level in CML patients was 0.061 5±0.062 4,which decreased to 0.009 4±0.006 7 upon CMoR,and remained remarkably higher 0.016 3±0.017 5 than that of normal donors (1.417±1.125)× 10-6,P 〈0.001.When relapse occurred,HO-1 expression significantly increased from 0.020 6±0.021 0 to 3.852±10.285 in CMoR stage and undergoing relapse.According to progression of CML,HO-1 expression level in CML patients increased from CP (0.009 5±0.017 6) to AP (0.028 0±0.055 7) and then to BP (0.276 7± 0.447 0).And there was a linear correlation between HO-1 expression and proportion
Wei SixiWang YatingChai QixiangFang QinZhang YamingLu YinghaoWang Jishi
关键词:PROGRESSIONRELAPSE
沙门菌感染相关噬血细胞综合征1例并文献复习
2018年
噬血细胞综合征也称为噬血细胞性淋巴组织细胞增生症和噬血细胞性网状细胞增生症,是一组病因及发病机制复杂的单核/巨噬细胞系统免疫缺陷导致的疾病[1]。噬血细胞综合征可发生于自身存在基因缺陷的个体,也可继发于感染、肿瘤及自身免疫性疾病。临床特点为持续高热,肝、脾、淋巴结肿大,全细胞减少,肝功能受损,凝血功能异常,血清铁蛋白升高及自然杀伤细胞活性降低等,部分患者出现神经系统症状,如嗜睡、易激惹、惊厥、脑神经麻痹、共济失调。
刘海峰王季石吴莉
关键词:沙门菌感染病例报告
自体造血干细胞移植治疗恶性淋巴瘤40例临床疗效分析被引量:5
2018年
目的探讨大剂量化疗联合自体造血干细胞移植(high dose therapy/autologous hematopoietic stem cell transplantation,HDT/AHSCT)在恶性淋巴瘤治疗中的临床疗效。方法选择2011年11月~2016年11月于笔者医院接受HDT/AHSCT治疗的的40例恶性淋巴瘤患者的病历资料。其中男性26例,女性14例,中位年龄为32(9~61)岁。非霍奇金淋巴瘤34例,霍奇金淋巴瘤6例。预处理方案为BEAM方案23例,BEAC方案10例,CBV方案7例。结果所有患者均采集到足够的外周血造血干细胞,且均成功获得造血重建。其中白细胞植活的中位时间为10(9~16)天;血小板植活的中位时间为13(9~29)天。所有患者均未发生移植相关死亡,移植前的完全缓解(CR)率为75%,部分缓解(PR)率为25%;移植后的CR率为95%,PR率为5%。中位随访21(2~60)个月,预期2年及3年的总生存率(OS)分别为81.8%及71.2%,2年及3年的无进展生存率(PFS)分别为72.2%和43.4%。其中27例(67.5%)患者存活,13例(32.5%)患者死亡。结论 HDT/AHSCT有造血重建快、并发症少、安全有效等优点,可作为治疗恶性淋巴瘤患者安全、有效的方法。
张奉齐王季石吴莉卢英豪
关键词:恶性淋巴瘤疗效
原发性浆细胞白血病1例并文献复习
2019年
浆细胞白血病(PCL)是一种罕见的、具有高度侵袭性的特殊类型白血病,属于浆细胞来源的恶性肿瘤,无多发性骨髓瘤(MM)病史,特征为外周血白细胞大于20%,计数大于2×10^9 L^-1[1]。原发性浆细胞白血病(PPCL)具有起病急、病情发展迅速、病程短等特点,对常规化疗、自体或异基因造血干细胞移植,预后差[2]。国内外有散在的病例报道显示,硼替佐米对PPCL有一定的疗效[3-5]。
阮涛王季石吴莉
关键词:硼替佐米造血干细胞移植浆细胞白血病
依鲁替尼治疗华氏巨球蛋白血症的研究进展
2020年
华氏巨球蛋白血症(WM)是以单克隆免疫球蛋白M(IgM)分泌为特征的淋巴浆细胞淋巴瘤,占其总数的90%~95%,属于少见的惰性B细胞淋巴瘤[1]。WM好发于男性,年发病率约3/100万,平均发病年龄为64~68岁[1-3],其临床表现为肿瘤侵犯组织器官和(或)单克隆IgM相关症状。有回顾性研究显示,WM较为常见的临床表现有贫血、B症状、淋巴结肿大、乏力、肝脾大等[3],但有超过25%的患者就诊时无症状[2]。该病发病率低、临床表现多样化,容易漏诊和误诊,且治愈率低,为临床诊治工作带来极大困难。
杨洁王季石吴莉(审校)
关键词:华氏巨球蛋白血症
共1页<1>
聚类工具0